If You Invested in Adia Nutrition (ADIA)

Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded healthcare company based in Winter Park, Florida. According to the company, it focuses on regenerative medicine, stem cell therapies, and wellness-oriented healthcare solutions. Through its operating divisions and subsidiaries, Adia Nutrition is involved in stem cell and regenerative product sales, specialized clinical services, and investments in aligned health and wellness businesses.

Business Model and Core Operations

Adia Nutrition states that it generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Its activities are organized around several key platforms:

• Adia Labs LLC – the company’s lab division, which the press releases describe as specializing in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink. Adia Labs is also described as expanding to include insurance-billable wound care products.
• Adia Med clinics – a clinical network that the company reports is growing nationwide. These clinics specialize in orthopedic care, pain management, and wound repair, and also offer a range of regenerative and advanced treatments.
• Strategic investments – Adia Nutrition reports that it invests in aligned businesses, including Cement Factory LLC, described as a nutrition and supplement company with a focus on health and wellness.

Across these platforms, Adia Nutrition describes a model that combines laboratory product development and distribution, clinic-based medical services, and equity participation in complementary wellness brands.

Regenerative and Advanced Therapies

Company disclosures describe Adia Med clinics as providing specialized regenerative treatments. According to the press releases, these include:

• Stem cell therapies, including the use of umbilical cord blood-derived stem cell and exosome products such as AdiaVita in certain clinical contexts.
• Platelet-rich plasma (PRP) treatments.
• Therapeutic plasma exchange (TPE), identified as an advanced treatment offered by Adia Med clinics.
• Autologous hematopoietic stem cell transplantation (aHSCT), which the company associates with its HSCT program for conditions such as multiple sclerosis and other autoimmune conditions.
• Wound repair services, supported by the company’s focus on wound care products and clinical wound management.

Adia Nutrition’s communications emphasize standardized, FDA-approved lab protocols in its lab operations and describe a focus on regenerative therapies that target orthopedic issues, pain, sports injuries, wound repair, and certain neurodevelopmental and autoimmune conditions, as reflected in its clinical initiatives.

Clinical Research and Autism Study

A notable element of Adia Nutrition’s activities is its clinical research through Adia Med of Winter Park, LLC. The company has announced a patent-pending clinical study titled “Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study,” listed on ClinicalTrials.gov under identifier NCT07304440.

According to the company’s news releases, this randomized interventional study is designed to enroll approximately 100 children ages 3–12 with a confirmed diagnosis of Autism Spectrum Disorder (ASD). The study evaluates whether combining AdiaVita—described as an umbilical cord blood-derived stem cell and exosome product—with glutathione therapy provides greater improvement in autism symptoms compared to glutathione therapy alone.

The trial design described by the company includes two initial groups: one receiving glutathione only, and another receiving glutathione plus monthly intravenous infusions of AdiaVita over an initial three-month phase. Outcomes are measured over a 24‑month period using the Autism Treatment Evaluation Checklist (ATEC), with additional attention to safety, tolerability, quality of life, and overall well-being through clinic visits, physical exams, blood tests, and adverse event monitoring. The company reports that the study received independent Institutional Review Board (IRB) approval from BeyondBound and that ClinicalTrials.gov has confirmed recruiting status.

Adia Labs and Clinic Partnerships

Adia Labs is described as a central engine for the company’s regenerative product offerings. The lab division distributes stem cell and regenerative products, including AdiaVita and AdiaLink, and is expanding into wound care products that can be billed to insurance. Through this lab platform, Adia Nutrition also supports clinic partners with access to regenerative products and diagnostic services.

The company reports that Adia Med clinics are expanding nationwide and that it is forming partnerships with physicians, clinics, and other healthcare practitioners. These relationships may include licensing the Adia Med name and integrating Adia’s regenerative therapies into existing practices in areas such as regenerative medicine, orthopedics, pain management, wellness, and wound care. Adia Nutrition has also highlighted marketing and oversight collaborations, including partnerships with organizations such as Axia MD for physician oversight and BoldMD for marketing and AI-powered tools in certain turnkey clinic models.

HSCT and Autoimmune Programs

Adia Nutrition has described an HSCT (hematopoietic stem cell transplantation) program through Adia Med, targeting conditions such as multiple sclerosis and other autoimmune diseases. Company communications reference physician-led, compliant approaches to bringing HSCT therapies to patients in the United States, along with educational initiatives such as webinars hosted with groups like HSCT Warriors. These activities are framed as part of the broader Adia Med platform focused on advanced regenerative and stem cell-based treatments.

Media, Education, and Outreach

Beyond clinical and laboratory operations, Adia Nutrition emphasizes media and educational outreach. The company has announced a media partnership between Adia Med and The Dr. Asa Network, led by physician and media personality Dr. Asa Andrew. Under this relationship, The Dr. Asa Network is expected to create content across radio, television, podcasts, docu-series, and digital channels focused on stem cell therapy, longevity medicine, and Adia Med’s story.

Adia Nutrition also highlights webinars, marketing campaigns, and clinic-focused education as part of its efforts to engage patients, providers, and investors. For example, it has referenced national television campaigns promoting U.S.-based stem cell treatments at its Winter Park clinic and educational events on HSCT and regenerative therapies.

Corporate Development and Capital Markets

In its public communications, Adia Nutrition notes that its common stock trades on the OTCQB Venture Market under the symbol ADIA. The company has reported an uplisting from OTC Pink to OTCQB and completion of requirements under SEC Rule 15c2‑11. It has also announced the submission of a Form 10 registration statement to the U.S. Securities and Exchange Commission, describing this as a step toward becoming a fully reporting company under the Securities Exchange Act of 1934.

Adia Nutrition’s disclosures describe a focus on enhancing transparency, corporate governance, and access to a broader investor base. The company has also referenced plans and aspirations related to potential future exchange listings, while emphasizing that the Form 10 filing itself is primarily a regulatory and reporting milestone.

Investment and Wellness Ecosystem

In addition to its core regenerative medicine and clinical operations, Adia Nutrition reports that it invests in businesses aligned with its health and wellness focus. One example cited is Cement Factory LLC, characterized as a nutrition and supplement company with shared values and an emphasis on wellness. Adia Nutrition has also mentioned prior divestiture of a non-core subsidiary to Cement Factory LLC while retaining an equity stake, as part of concentrating on its regenerative medicine strategy.

Across its disclosures, the company presents itself as building an ecosystem that includes regenerative products, clinical services, wellness brands, and partnerships with medical and media entities. Its stated aim is to expand access to regenerative therapies and wellness solutions through standardized lab protocols, clinic networks, and collaborative ventures.

Company Positioning

Adia Nutrition consistently describes itself as advancing healthcare through innovation in regenerative medicine and stem cell technologies. Its operations span lab-based product development, clinical service delivery, clinical research, and strategic investments. For investors and observers, the ADIA stock represents exposure to a business model centered on regenerative therapies, clinic partnerships, and wellness-focused products, as characterized in the company’s own public statements.